EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications.The ...

Type 2 diabetes, some infections and certain cancers. “Acute inflammation is a recovery process that enables the body to repair its tissues and eliminate pathogens,” says Lucia Stansbie ...

The submitted indications are for add-on maintenance treatment of asthma in adult and adolescent patients aged 12 years and older with type 2 inflammation characterised by an eosinophilic phenotype ...

Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...

“Our STAT6 program represents a significant advancement in the discovery of an oral inhibitor for type 2 inflammatory ... the treatment of asthma, atopic dermatitis, COPD and other inflammatory ...